美國InVivoScribe  www.invivoscribe.com
美國Invivoscribe公司致力于通過為分子診斷、血液病學(xué)研究診斷和cDNA合成提供高品質(zhì)、可信賴、尖端的產(chǎn)品來提高世界醫(yī)療保健的水平。 
1995年，在擁有體內(nèi)cDNA合成技術(shù)專利的基礎(chǔ)上Invivoscribe公司成立了。這種體內(nèi)cDNA合成技術(shù)能在活細(xì)胞和組織中使不穩(wěn)定的分子信使RNA轉(zhuǎn)化為穩(wěn)定存在的cDNA，從而提高了cDNA產(chǎn)物的質(zhì)量和多產(chǎn)性，避免了通過RNA提取在體內(nèi)合成cDNA的困難和缺點(diǎn)。Invivoscribe提供了全面的依靠PCR技術(shù)的基因重組、染色體轉(zhuǎn)位、基因突變的檢測試劑和對(duì)照?？蛻舯椴荚谑澜绺黝I(lǐng)先制藥和生物技術(shù)行業(yè)、醫(yī)學(xué)中心、癌癥研究中心和分子檢測中心等領(lǐng)域。Invivoscribe研究的體內(nèi)診斷產(chǎn)品是用于白血病、淋巴瘤和淋巴組織增生性疾病的診斷和分類。具體檢測指標(biāo)有IgH基因重排、TCRB/TCRD/TCRG基因重排、BCL1/JH轉(zhuǎn)位、BCR/ABL轉(zhuǎn)位、FLT3突變以及PML/PARα轉(zhuǎn)位等。 
作為優(yōu)選試驗(yàn)的組織，Invivoscribe公司為制藥行業(yè)的發(fā)展提供檢測和其他服務(wù)，同時(shí)也為特異性分析平臺(tái)提供原始試劑。 
Invivoscribe的基因重組產(chǎn)品和某些基因突變檢測產(chǎn)品是唯一獲得專利的產(chǎn)品。 
最新產(chǎn)品：Invivoscribe廠家最新發(fā)展了符合歐洲標(biāo)準(zhǔn)的體外診斷產(chǎn)品。

invivoscribe的淋巴瘤、白血病的體外診斷試劑包括： 
（1）試劑盒 包括B Cell Gene Rearrangement/Clonality Assays（B細(xì)胞基因重排分析）, T cell 
Gene Rearrangement/Clonality Assays（T細(xì)胞基因重排分析）, Translocation Assays（轉(zhuǎn)位分析） 
和Mutation Assays（突變分析）。 
（2）特異分析試劑 包括IGH (Immunoglobulin Heavy Chain), IGK (Immunoglobulin Kappa Light 
Chain), IGL (Immunoglobulin Lambda Light Chain), TCRB (T Cell Receptor Beta Chain), TCRD( 
T Cell Receptor Delta Chain), TCRG (T Cell Receptor Gamma Chain), BCL2/JH t(14;18), 
BCR/ABL t(9;22), FLT3 Mutation. 
（3）CE Marked Diagnostic Assays 
- IdentiClone™ IGH Gene Rearrangement and Clonality Assays 
- IdentiClone™ IGK Gene Rearrangement and Clonality Assays 
- IdentiClone™ IGL Gene Rearrangement and Clonality Assays 
- IdentiClone™ TCRB Gene Rearrangement and Clonality Assays 
- IdentiClone™ TCRD Gene Rearrangement and Clonality Assays 
- IdentiClone™ TCRG Gene Rearrangement and Clonality Assays 
- IdentiClone™ BCL1/JH t(11;14) Translocation Assays 
- IdentiClone™ BCL2/JH t(14;18) Translocation Assays
invivoscribe的淋巴瘤、白血病的體外診斷試劑的檢測方法包括： 
（1）Gel detection：樣本、標(biāo)準(zhǔn)品都跑PAGE膠 
（2）ABI Fluorescence Detection 要求用6FAM,HEX,或者NED熒光素標(biāo)記 
（3）Beckman Coulter CE/NAT Platforms 要求用D4,D3或者D2熒光素標(biāo)記 
（4）cy5.0 Fluorescence Detection 
（5）Probe-Based for Quantitative Real-Time Detection 
（6）SYRB-Green for Quantitative Real-Time Detection 

InVivoScribe Technologies is a privately-held biotechnology company located in San Diego, California, with a sales and distribution office (InVivoScribe Technologies, SARL) located in La Ciotat, Provence, France.
The company is dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge tools for molecular diagnostics, hematopathology and cDNA synthesis.
The company was founded in 1995 based upon InVivoScribe's patented in vivo cDNA synthesis technologies. These technologies convert unstable cellular messenger RNA into stable complementary DNA within the living cells and tissues - enhancing the quality and reproducibility of cDNA products and eliminating difficulties and bias associated with RNA extraction and in vitro methods for cDNA synthesis.
InVivoScribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation testing reagents and controls. Customers include many of the world's leading pharmaceutical and biotechnology companies, medical centers, cancer research centers, reference laboratories and molecular testing centers.
Our research and in vitro diagnostic products are used to identify, classify and follow leukemias, lymphomas and other lymphoproliferative disease.
As a contract research organization, InVivoScribe provides tests and services to assist in the development of pharmaceutical agents and devices. We also produce OEM Reagents dedicated for use with specific analytical platforms.
InVivoScribe's gene rearrangement products, and certain of our gene mutation testing products are covered by exclusive-licensed patents. The company is debt-free and has been profitable since the beginning of this decade.